Action on AMD

Queen’s University Belfast’s Dr Imre Lengyel discusses new research which could pave the way to earlier treatment strategies for age-related macular degeneration.

 

The leading cause of sight loss in development countries, age-related macular degeneration (AMD) is roughly twice as common as Alzheimer’s among older people – and growing. By 2020, it is projected to affect some 196 million people, rising to a massive 288 million by 2040. But while AMD can now be treated with an injection of anti-vascular endothelial growth factor (VEGF), there is currently no treatment available for the most common dry form of AMD.

 

More information can be found here.